Evidence map›Paper›PMID 31156037›Full record

ArticleRNA biology2019

NET-prism enables RNA polymerase-dedicated transcriptional interrogation at nucleotide resolution.

Constantine Mylonas, Peter Tessarz

Abstract read
In one paragraph

Article in RNA biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Mechanisms of Transcriptional Pausing in Bacteria.Journal of molecular biology · 2019
    Review
  5. Structure and function of the histone chaperone FACT - Resolving FACTual issues.Biochimica et biophysica acta. Gene regulatory mechanisms · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Constantine Mylonasa Max Planck Research Group 'Chromatin and Ageing', Max Planck Institute for Biology of Ageing , Cologne , Germany.
Peter Tessarza Max Planck Research Group 'Chromatin and Ageing', Max Planck Institute for Biology of Ageing , Cologne , Germany.ORCID 0000-0002-6953-9835

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of quantitative approaches that enable interrogation of transcription at single nucleotide resolution has allowed a novel understanding of transcriptional regulation previously undefined. However, little is known, at such high resolution, how transcription factors directly influence RNA Pol II pausing and directionality. To map the impact of transcription/elongation factors on transcription dynamics genome-wide at base pair resolution, we developed an adapted NET-seq protocol called NET-prism (Native Elongating Transcription by Polymerase-Regulated Immunoprecipitants in the Mammalian genome). Application of NET-prism on elongation factors (Spt6, Ssrp1), splicing factors (Sf1), and components of the pre-initiation complex (PIC) (TFIID, and Mediator) reveals their inherent command on transcription dynamics, with regards to directionality and pausing over promoters, splice sites, and enhancers/super-enhancers. NET-prism will be broadly applicable as it exposes transcription factor/Pol II dependent topographic specificity and thus, a new degree of regulatory complexity during gene expression.

Indexed as

Transcription, GeneticDNA-Binding ProteinsGene Expression RegulationGenomeHumansNucleotidesPhosphorylationPromoter Regions, GeneticRNA Polymerase IIRNA SplicingSequence Analysis, RNATranscriptional Elongation FactorsDNA-Binding ProteinsNucleotidesRNA Polymerase IITranscriptional Elongation Factorselongation factorsRNA splicingTranscriptiontranscription factors

Identifiers

PMID31156037
PMCPMC6693550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.